Biopharma industry confidence at highest in years despite geopolitical headwinds
Biopharma executives’ confidence in the industry has reached its highest point in four years, reflecting a successful navigation through a …
Post
-
-
Voro and Alloy partner on tumour-selective TCE therapeutics
Voro Therapeutics and Alloy Therapeutics have formed a strategic research partnership to develop tumour-selective, next-generation masked T-cell engager (TCE) therapeutics. The …
-
Biogen to acquire RayThera for up to $1bn
Biogen has entered a definitive agreement to acquire RayThera, a biotechnology company specialising in small-molecule therapies for immunology, for up …
-
ASCO26: RLTs bring the buzz, but commercial and tolerability qualms remain
Upon its rise to notoriety spearheaded by drugs like Novartis’ Pluvicto (lutetium Lu 177 vipivotide tetraxetan), the radiopharmaceutical field is …
-
How biotech executives are confronting the funding and regulatory shifts
Following an influx of capital in the early COVID-19 pandemic, the biotech sector entered a sustained investment slump. Now the …
-
UniQure to seek approval of Huntington’s gene therapy after FDA U-turn
UniQure has confirmed it will submit its Huntington’s disease gene therapy for regulatory review, after the US Food and Drug …
-
Global semiconductors hiring slows after Q1 surge: What this means for your sector
For company leaders, detailed hiring and workforce data is an early warning system for performance. It shows where skills are …
-
ADA26: retatrutide delivers unprecedented weight loss in Phase III TRIUMPH-1
On 6 June, at the 86th Scientific Sessions of the American Diabetes Association (ADA) in New Orleans, Louisiana, findings from …
-
Jazz and AbCellera sign deal for T-cell engagers in solid tumours
Jazz Pharmaceuticals and AbCellera have signed a preclinical research, option, and licence agreement for the discovery and development of T-cell-engaging …
-
LG AI Research and D&D Pharmatech sign agreement for oral peptide drugs
LG AI Research and D&D Pharmatech have entered an agreement to collaborate on the development of next-generation oral peptide drugs, …
-
Complementing DepMap: Expanding the toolkit for oncology target discovery and de-risking
With cancer responsible for one in six deaths around the world, precision medicines based on the root cause of the …
-
Biopharma bounces back as M&A impetus fuels recovery
Following the largest dealmaking quarter in six years, PwC analysts have empirically stated that the biopharma ecosystem is “back to …
-
Vedana debuts with $46m to progress migraine therapies
Vedana Therapeutics has emerged with $46m in hand from a Series A financing round, which will fund the Seattle-based biotech’s …
-
Can AI predict the (regulatory) future?
The use of AI in pharma has expanded from pilots to function-specific projects with the development of more agile tools. …
-
AviadoBio broadens vMiX gene silencing licence with King’s College London
AviadoBio has extended its exclusive licence agreement with King’s College London to apply the vMiX ribonucleic acid interference (RNAi) gene-silencing …
